K. Luk

发表

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

A. Polonskaia, C. Lukacs, Hongmao Sun, 2013, Bioorganic & medicinal chemistry letters.

3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.

U. Kammlott, C. Lukacs, Yi Chen, 2003, Bioorganic & medicinal chemistry letters.

A new series of potent oxindole inhibitors of CDK2.

Thelma Thompson, U. Kammlott, Yi Chen, 2004, Bioorganic & medicinal chemistry letters.

Rational design of highly selective spleen tyrosine kinase inhibitors.

Johannes C. Hermann, A. Kuglstatter, K. Luk, 2012, Journal of medicinal chemistry.

Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.

Yi Chen, K. Luk, A. Railkar, 2006, Bioorganic & medicinal chemistry letters.

N-acyl phenylalanine analogues as potent small molecule VLA-4 antagonists.

K. Luk, J. Tilley, R. Trilles, 2000, Bioorganic & medicinal chemistry letters.

Preclinical Development Inactivation of Mirk / Dyrk 1 b Kinase Targets Quiescent Pancreatic Cancer Cells

A. Polonskaia, K. Luk, E. Friedman, 2011 .

Synthesis of potent oxindole CDK2 inhibitors.

K. Luk, W. Depinto, A. Dermatakis, 2003, Bioorganic & medicinal chemistry.

DNA‐Compatible Chemistry

K. Luk, A. Satz, 2014 .

A novel synthesis of the monobactam antibiotic carumonam

K. Luk, S. Choudhry, P. Manchand, 1988 .

Four new mycotoxins of Aspergillus clavatus related to tryptoquivaline.

K. Luk, G. Büchi, B. Kobbe, 1977, The Journal of organic chemistry.

Organometallic reagent-mediated one-pot synthesis of 3,5,6-trisubstituted naphthostyrils

K. Luk, Jinjun Liu, F. Konzelmann, 2003 .

Production of cyclopiazonic acid by Aspergillus flavus Link

K. Luk, B. Kobbe, J. M. Townsend, 1977, Applied and environmental microbiology.

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

S. J. Clark, J. Kappes, J. Lifson, 1993, Science.

A novel and convenient method for the synthesis of substituted naphthostyrils

K. Luk, Jinjun Liu, F. Konzelmann, 2003 .

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.

L. Vassilev, B. Graves, Z. Filipovic, 2014, Bioorganic & medicinal chemistry.

Improvement of the bioavailability of the anti-herpes virus agent BVDU by use of 5'-O-alkoxycarbonyl derivatives with increased metabolic stability.

K. Luk, D. Sutton, M. R. Harnden, 1986, Journal of Antimicrobial Chemotherapy.

RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.

K. Luk, A. Railkar, B. Higgins, 2005, Bioorganic & Medicinal Chemistry.

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Yi Chen, Zhi Chen, K. Luk, 2012, Bioorganic & Medicinal Chemistry Letters.

Isolation and identification of "diazepam-like" compounds from bovine urine.

R. O'brien, K. Luk, M. Weigele, 1983, Journal of natural products.

Synthesis of aflatoxin Q1.

K. Luk, G. Büchi, P. M. Müller, 1975, The Journal of organic chemistry.

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

A. Polonskaia, K. Luk, E. Friedman, 2011, Molecular Cancer Therapeutics.

Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.

K. Luk, P. Wovkulich, C. Tovar, 2013, ACS medicinal chemistry letters.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.

Johannes C. Hermann, John Menke, A. Kuglstatter, 2013, Journal of medicinal chemistry.